Green Cross Holdings Preference Shares (005257) - Total Liabilities
Based on the latest financial reports, Green Cross Holdings Preference Shares (005257) has total liabilities worth ₩2.40 Trillion KRW (≈ $1.63 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Green Cross Holdings Preference Shares - Total Liabilities Trend (2013–2024)
This chart illustrates how Green Cross Holdings Preference Shares's total liabilities have evolved over time, based on quarterly financial data. See 005257 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Green Cross Holdings Preference Shares Competitors by Total Liabilities
The table below lists competitors of Green Cross Holdings Preference Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
APOLLO GROUP-A
F:APO
|
Germany | €1.28 Million |
|
Icon Energy Ltd
AU:ICN
|
Australia | AU$5.80 Million |
|
Newpeak Metals Ltd
AU:NPM
|
Australia | AU$368.94K |
|
Victorian Plumbing Group PLC
LSE:VIC
|
UK | GBX122.30 Million |
|
Cascadero Copper Corp
V:CCD
|
Canada | CA$863.86K |
|
RevoluGROUP Canada Inc
V:REVO
|
Canada | CA$1.11 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Green Cross Holdings Preference Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Green Cross Holdings Preference Shares worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Green Cross Holdings Preference Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Green Cross Holdings Preference Shares (2013–2024)
The table below shows the annual total liabilities of Green Cross Holdings Preference Shares from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩1.82 Trillion ≈ $1.23 Billion |
-2.03% |
| 2023-12-31 | ₩1.86 Trillion ≈ $1.26 Billion |
+14.22% |
| 2022-12-31 | ₩1.63 Trillion ≈ $1.10 Billion |
+2.45% |
| 2021-12-31 | ₩1.59 Trillion ≈ $1.07 Billion |
+1.17% |
| 2020-12-31 | ₩1.57 Trillion ≈ $1.06 Billion |
+23.71% |
| 2019-12-31 | ₩1.27 Trillion ≈ $858.81 Million |
+7.81% |
| 2018-12-31 | ₩1.18 Trillion ≈ $796.61 Million |
+4.86% |
| 2017-12-31 | ₩1.12 Trillion ≈ $759.70 Million |
+28.52% |
| 2016-12-31 | ₩872.27 Billion ≈ $591.12 Million |
+16.10% |
| 2015-12-31 | ₩751.28 Billion ≈ $509.13 Million |
+23.20% |
| 2014-12-31 | ₩609.81 Billion ≈ $413.26 Million |
+16.27% |
| 2013-12-31 | ₩524.46 Billion ≈ $355.42 Million |
-- |
About Green Cross Holdings Preference Shares
Green Cross Holdings Corporation operates as a biotechnology company. The company provides prescription drugs and over the counter drugs; aseptic fill and finish services for drug manufacturing; and pharmaceutical logistics services. It also researches and develops plasma derivatives for von Willebrand disease and primary immunodeficiency; vaccines for mRNA flu, anthrax, tetanus, diphtheria, pert… Read more